TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Heart Test Laboratories, Inc. ( (HSCS) ) has shared an update.
Heart Test Laboratories, Inc. announced on November 28, 2025, that its Board of Directors approved an amendment to the company’s 2023 Equity Incentive Plan. This amendment increases the maximum number of shares of common stock that can be issued under the plan to 1,250,000 shares, subject to shareholder approval. Additionally, the Board approved the grant of restricted shares and restricted stock unit awards to executives, non-employee directors, and employees, with specific vesting conditions. These changes are aimed at enhancing the company’s equity compensation framework and aligning the interests of stakeholders with the company’s growth objectives.
The most recent analyst rating on (HSCS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Heart Test Laboratories, Inc. stock, see the HSCS Stock Forecast page.
Spark’s Take on HSCS Stock
According to Spark, TipRanks’ AI Analyst, HSCS is a Neutral.
Heart Test Laboratories, Inc. is struggling with significant financial challenges, as reflected in its poor financial performance score. The technical analysis indicates bearish momentum, and the valuation is unattractive due to negative earnings. These factors contribute to a low overall stock score.
To see Spark’s full report on HSCS stock, click here.
More about Heart Test Laboratories, Inc.
Average Trading Volume: 54,654
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.07M
For detailed information about HSCS stock, go to TipRanks’ Stock Analysis page.